logo
Share SHARE
FONT-SIZE Plus   Neg

Novavax RSV Vaccine Mid-Stage Trial Shows Positive Results

Shares of Novavax Inc.(NVAX) rose over five percent in after-hours trade Tuesday after its mid-stage study of a vaccine for the treatment of respiratory diseases in women of childbearing age met trial goals.

Top-line data from the phase II trial of respiratory syncytial virus (RSV) vaccine candidate in women of childbearing age accomplished the trial's protocol-specified objectives and supports progression to the next stage of advanced clinical testing, the company said in a statement.

Novavax said the the antibodies in vaccinated women can be expected to be naturally transferred to their infants in utero and thereby may confer passive protection at the earliest stage of life when these infants are extremely vulnerable to severe respiratory disease due to the virus.

The mid-stage study enrolled 330 women of childbearing age who received either one or two injections of a single-dose of vaccine or placebo. The trial evaluated the safety and immunogenicity of two doses of vaccine with and without aluminum phosphate as an adjuvant.

Novavax said the vaccine was well-tolerated and the safety profile was similar to that observed in the early-stage clinical trial.

"These results confirm that our RSV vaccine candidate has the potential to induce clinically useful immunity and has raised no safety concerns. The primary immunogenicity measures confirmed that the vaccine is a potent antigen and the aluminum phosphate adjuvant further enhanced the antibody responses," said Gregory Glenn SVP and Chief Medical Officer of Novavax.

NVAX closed Tuesday's trading at $2.35, down $0.02 or 0.84%, on a volume of 1.8 million shares on the Nasdaq. The stock gained $0.13 or 5.53% in after-hours trade.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Embark Veterinary Inc., a startup that makes dog DNA-testing kits for pet owners, vets and breeders, said it has raised $4.5 million in funding from investors and relocated its headquarters to Boston. The company intends to use the new funding to expand its canine genetic testing suite for pet owners, breeders, and veterinarians. Intel Corp. has completely shut down its wearables division about two weeks ago, CNBC reported, citing a person familiar with the matter. The company reportedly intends to focus on augmented reality. According to the CNBC report, Intel laid off about 80 percent of the team that made the Basis fitness watch in November 2016 and has now eliminated the division entirely. The Federal Trade Commission is investigating allegations that Amazon.com Inc. misled consumers about its pricing discounts, Reuters reported, citing a source close to the probe. The FTC probe is reportedly part of the agency's review of Amazon's proposed $13.4 billion deal to buy grocery chain Whole Foods Market Inc.
comments powered by Disqus
Follow RTT